key: cord-0780339-ieh8uozr
authors: Schwaiger, Julia; Karbiener, Michael; Aberham, Claudia; Farcet, Maria R.; Kreil, Thomas R.
title: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic
date: 2020-07-30
journal: bioRxiv
DOI: 10.1101/2020.07.30.228213
sha: f2fc34e87b70d48beb4ebfcd5d84dcbffcbf229b
doc_id: 780339
cord_uid: ieh8uozr

The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing antibodies to the new species in humans is unclear. The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 IVIG preparations, produced from plasma collected in Europe and the US, highly potent neutralization of a seasonal coronavirus was confirmed, yet no cross-neutralization of the new SARS-CoV-2 was seen. SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.

antibodies against the pathogens in their environment. Testing 54 IVIG preparations, produced 48 from plasma collected in Europe and the US, highly potent neutralization of a seasonal 49 coronavirus was confirmed, yet no cross-neutralization of the new SARS-CoV-2 was seen. The question is of significant clinical relevance, as SARS-CoV-2 cross-neutralizing antibodies in 86 IVIGs, if they were present, might afford some protection to PIDs, and may even represent a 87 treatment option for COVID-19 patients. 

The validity and reliability of the SARS-CoV-2 neutralization assay used in the current study was 146 demonstrated by the analysis of 100 convalescent plasma donations from PCR-confirmed SARS-

CoV-2 cases [9] . As controls, two plasma samples collected before the emergence of SARS- Figure 1A ).

In contrast, hCoV-229E nAb titers between 1:43 and 1:196 (mean=1:98) were measured for the 156 54 IVIG lots tested ( Figure 1B) . IVIG lots produced from recovered plasma contained 157 significantly higher levels of nAb to hCoV-229E as compared to IVIG lots produced from source 158 plasma, independent of the geography of origin. A significant, although quantitatively minor, 159 difference was also found between IVIG lots manufactured from source plasma collected in 160 either the US or the EU. 

Testing a total of 560 plasma pools of 6 donations each, in total reflective of 3,360 plasma 169 donations, from CW 13 until CW 28, 2020 revealed that most of these pools had SARS-CoV-2 170 µNT titers below the limit of detection ( Table 1 ). The first pool with detectable nAbs to SARS- (Table 1) .

Our analysis of IVIG lots revealed high nAb titers to hCoV-229E ( Figure 1B) . It is 178 interesting to note that in IVIG lots produced from recovered plasma significantly higher titers to 179 hCoV-229E were found compared to IVIG lots produced from source plasma, independent of Abbreviations: LOD, limit of detection; µNT50, neutralization titer for 50% of the wells 300 a SARS-CoV-2 PCR-positive individuals per 100,000 population in Austria are described as cumulative COVID-19 incidence in percent. 

West Nile virus infection in plasma of blood and 242 plasma donors, United States

Update on Human Rhinovirus and Coronavirus Infections

Epidemiology of 246 Seasonal Coronaviruses: Establishing the Context for the Emergence of Coronavirus Disease 247 2019

Human 249 coronavirus circulation in the United States

Inhibition 251 of human coronavirus NL63 infection at early stages of the replication cycle

Lack of cross-neutralization by SARS patient sera 254 towards SARS-CoV-2

A systematic review of antibody 256 mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and 257 association of antibody responses with severity of disease

Severe Acute Respiratory Syndrome Coronavirus 2-261

Specific Antibody Responses in Coronavirus Disease Patients

Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations

Antibodies to coronaviruses are higher in older compared 268 with younger adults and binding antibodies are more sensitive than neutralizing antibodies in 269 identifying coronavirus-associated illnesses

Cross-reactive antibodies in convalescent SARS patients' 271 sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent 272 and neutralizing antibody tests

Currently available intravenous immunoglobulin contains 274 antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

Cross-neutralization activity against SARS-CoV-277 2 is present in currently available intravenous immunoglobulins

A serological assay to detect SARS-CoV-2 281 seroconversion in humans

Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative 283